A recent study done in the U.S. showed that semaglutide and tirzepatide — injectable GLP-1 drugs for obesity — produce lower weight loss in a real-world setting, than during the clinical trial, because patients discontinue treatment or use lower main…
New ‘weight-loss’ drugs have lower impact in real life compared to clinical trial results: study
